Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307.
Business Wire › October 29, 2009
Linked as:
Extract
Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307.
--Data presented at iSBTc meeting; Phase 2 initiation in first quarter 2010--
NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer. CDX-1307, the first...See the full content of this document
Sponsored links
